Research progress of mesenchymal stem cells in the treatment of liver disease
Liver disease is a serious threat to human health. However, there is still no effective medical treatment for end-stage liver diseases such as cirrhosis and liver failure. Mesenchymal stem cells (MSCs) are expected to be used clinically for liver cirrhosis caused by various etiologies, acute-on-chro...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
2023-01-01
|
| Series: | Jichu yixue yu linchuang |
| Subjects: | |
| Online Access: | http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2023-43-1-12.pdf |
| _version_ | 1797366380474925056 |
|---|---|
| author | ZHOU Jiahang, CHEN Junyao, CAO Hongcui |
| author_facet | ZHOU Jiahang, CHEN Junyao, CAO Hongcui |
| author_sort | ZHOU Jiahang, CHEN Junyao, CAO Hongcui |
| collection | DOAJ |
| description | Liver disease is a serious threat to human health. However, there is still no effective medical treatment for end-stage liver diseases such as cirrhosis and liver failure. Mesenchymal stem cells (MSCs) are expected to be used clinically for liver cirrhosis caused by various etiologies, acute-on-chronic liver failure, chronic liver failure, and complications post-liver transplantation by their multi-directional differentiation and immunomodulatory abilities. MSCs can directly differentiate into hepatocyte-like cells and indirectly secrete soluble factors to achieve goals such as antioxidant, anti-regulated cell death, anti-fibrosis, inhibiting inflammation, inhibiting immune response, etc., so to reduce liver damage and improve survival rate. A sound quality standard evaluation system and a more in-depth mechanism exploration are the prerequisites for MSCs to be used in the clinical treatment of liver diseases in the future. |
| first_indexed | 2024-03-08T17:03:20Z |
| format | Article |
| id | doaj.art-bdc1eee08fed4e1ebfd27e27e5aeacb1 |
| institution | Directory Open Access Journal |
| issn | 1001-6325 |
| language | zho |
| last_indexed | 2024-03-08T17:03:20Z |
| publishDate | 2023-01-01 |
| publisher | Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. |
| record_format | Article |
| series | Jichu yixue yu linchuang |
| spelling | doaj.art-bdc1eee08fed4e1ebfd27e27e5aeacb12024-01-04T07:27:26ZzhoInstitute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.Jichu yixue yu linchuang1001-63252023-01-01431122010.16352/j.issn.1001-6325.2023.01.0012Research progress of mesenchymal stem cells in the treatment of liver diseaseZHOU Jiahang, CHEN Junyao, CAO Hongcui0State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaLiver disease is a serious threat to human health. However, there is still no effective medical treatment for end-stage liver diseases such as cirrhosis and liver failure. Mesenchymal stem cells (MSCs) are expected to be used clinically for liver cirrhosis caused by various etiologies, acute-on-chronic liver failure, chronic liver failure, and complications post-liver transplantation by their multi-directional differentiation and immunomodulatory abilities. MSCs can directly differentiate into hepatocyte-like cells and indirectly secrete soluble factors to achieve goals such as antioxidant, anti-regulated cell death, anti-fibrosis, inhibiting inflammation, inhibiting immune response, etc., so to reduce liver damage and improve survival rate. A sound quality standard evaluation system and a more in-depth mechanism exploration are the prerequisites for MSCs to be used in the clinical treatment of liver diseases in the future.http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2023-43-1-12.pdfliver disease|mesenchymal stem cells|clinical treatment|mechanism |
| spellingShingle | ZHOU Jiahang, CHEN Junyao, CAO Hongcui Research progress of mesenchymal stem cells in the treatment of liver disease Jichu yixue yu linchuang liver disease|mesenchymal stem cells|clinical treatment|mechanism |
| title | Research progress of mesenchymal stem cells in the treatment of liver disease |
| title_full | Research progress of mesenchymal stem cells in the treatment of liver disease |
| title_fullStr | Research progress of mesenchymal stem cells in the treatment of liver disease |
| title_full_unstemmed | Research progress of mesenchymal stem cells in the treatment of liver disease |
| title_short | Research progress of mesenchymal stem cells in the treatment of liver disease |
| title_sort | research progress of mesenchymal stem cells in the treatment of liver disease |
| topic | liver disease|mesenchymal stem cells|clinical treatment|mechanism |
| url | http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2023-43-1-12.pdf |
| work_keys_str_mv | AT zhoujiahangchenjunyaocaohongcui researchprogressofmesenchymalstemcellsinthetreatmentofliverdisease |